The FDA alerted pharmaceutical companies that it will hold them accountable for the advertising and marketing activities of their subsidiaries, including pharmacy benefit management companies.
The FDA alerted pharmaceutical companies that it will hold them accountable for the advertising and marketing activities of their subsidiaries, including pharmacy benefit management companies.
Under the guidelines, PBMs must submit copies of all advertisements, brochures and other promotional materials for FDA review.
In its proposed guidance for industry, the FDA stated: "Generally, a medical product sponsor will be held responsible for promotional activities performed by its health care organization or PBM subsidiary that violate the act or regulations (e.g., the dissemination of false or misleading labeling or advertising). Promotional labeling and advertising disseminated by the subsidiary are subject to the existing post-marketing reporting requirements."
In the past, the FDA has not regulated the promotional practices of PBMs because their traditional role was to manage health care costs. However, recent marriages between several PBMs and large pharmaceutical manufacturers have raised concerns at the FDA.
One major concern is that pharmaceutical manufacturers could use their clout to influence which prescription products their affiliated PBMs select and market to health care-purchasing customers.
Pharmaceutical companies that lack similar relationships have complained that the pairings create an unfair marketing and promotional loophole.
In its guidance, the FDA acknowledged that it "generally does not exercise jurisdiction over materials disseminated by individuals or entities that are not in any way affiliated with a medical product sponsor." However, the agency continued, "the sponsor should not be permitted to avoid regulations by changing the form through which their communication is accomplished."
The FDA said it would allow for a 90-day comment period before issuing a final guidance. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.